CGT_Live Profile Banner
CGTLive® Profile
CGTLive®

@CGT_Live

Followers
641
Following
226
Media
412
Statuses
8K

CGTLive delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.

Joined December 2020
Don't wanna be here? Send us removal request.
@CGT_Live
CGTLive®
2 days
With the aim of getting a cross-section of the current state of progress in #celltherapy for #solidtumors, CGTLive® reached out to several experts to get their insight into some notable approaches under evaluation. #oncology #CART #solidtumor. More:.
0
0
0
@CGT_Live
CGTLive®
7 hours
ICYMI:. RP-A701 utilizes an AAVrh.74 vector and constitutes a first-in-class treatment for BAG3-DCM. #genetherapy #CardiologyTwitter #cardiomyopathy @RocketPharma. Read more:.
0
0
0
@CGT_Live
CGTLive®
9 hours
ICYMI:. With the removal of the REMS requirement, hospitals and clinics that provide these therapies no longer necessitate a specific certification. #CART #celltherapy #FDA @US_FDA. Read more:.
0
0
0
@CGT_Live
CGTLive®
11 hours
"This is encouraging for us because it does potentially pave the path for us exploring the ability to redose our therapy. " -Derek Jackson, BS, MA (@PaciraBio). #osteoarthritis #genetherapy #KneeOsteoarthritis #ASGCT2025 . Watch:.
0
0
0
@CGT_Live
CGTLive®
16 hours
The 24 patients in group 1 who received rilparencel showed stabilization of kidney function following treatment, with a 78% improvement in annual decline in eGFR slope. #diabetes #KidneyDisease #CKD #celltherapy @ProKidney. Read more:.
0
0
0
@CGT_Live
CGTLive®
1 day
SNUG01 has previously been evaluated in an investigator-initiated trial in China that was completed recently, according to @Sineugene_2021. #ALS #genetherapy #AmyotrophicLateralSclerosis. Read more:.
0
0
0
@CGT_Live
CGTLive®
2 days
Notably, @CARsgen_Ther received priority review for satri-cel from the NMPA in May 2025 for the indication covered in the NDA. #GastricCancer #CART #celltherapy. Read more:.
0
0
0
@CGT_Live
CGTLive®
5 days
With the removal of the REMS requirement, hospitals and clinics that provide these therapies no longer necessitate a specific certification. #CART #celltherapy #FDA @US_FDA. Read more:.
0
0
1
@CGT_Live
CGTLive®
5 days
This Fourth of July, we honor the relentless pursuit of progress that transforms patient care and shapes the future of medicine. Wishing everyone a safe and inspiring holiday. #FourthofJuly #IndependenceDay
0
0
0
@CGT_Live
CGTLive®
6 days
ICYMI:. Our team has highlighted several important actions including the @US_FDA granting its new platform designation to @Sarepta and clearing an IND application for #Nuevocor's LMNA DCM #genetherapy. #celltherapy. More:.
0
0
1
@CGT_Live
CGTLive®
6 days
ICYMI:. "I personally have seen very positive outcomes as far as efficacy in all that I've treated so I think that's very exciting." -Tami John, MD (@StanfordMed). #thalassemia #genetherapy #hematology. More:.
0
0
0
@CGT_Live
CGTLive®
7 days
RP-A701 utilizes an AAVrh.74 vector and constitutes a first-in-class treatment for BAG3-DCM. #genetherapy #CardiologyTwitter #cardiomyopathy @RocketPharma. Read more:.
0
0
0
@CGT_Live
CGTLive®
8 days
Patients with DLBCL who were treated with tisa-cel, axi-cel, or liso-cel across their FDA-approved indications did not show statistically significant differences in overall survival. #lymsm #lymphoma #EHA2025. Read more:.
0
0
0
@CGT_Live
CGTLive®
8 days
Last month delivered data updates from several conferences, including #ASCO25, #ADASciSessions, and #EHA2025. Click here:.
0
1
1
@CGT_Live
CGTLive®
8 days
ICYMI:. ". so far, for both products, we haven't seen numbers that indicate one is more difficult or problematic than the other." -Tami John, MD (@StanfordMed). #thalassemia #genetherapy #hematology. Watch now:.
0
0
0
@CGT_Live
CGTLive®
8 days
Our team has highlighted several important actions including the @US_FDA granting its new platform designation to @Sarepta and clearing an IND application for #Nuevocor's LMNA DCM #genetherapy. #celltherapy. More:.
0
1
0
@CGT_Live
CGTLive®
8 days
ICYMI:. According to enGene, data from the phase 1/2 LEGEND study informed the FDA’s decision to grant RMAT designation to detalimogene. #genetherapy #BladderCancer #oncology. Read more:.
0
0
0
@CGT_Live
CGTLive®
9 days
"I personally have seen very positive outcomes as far as efficacy in all that I've treated so I think that's very exciting." -Tami John, MD (@StanfordMed). #thalassemia #genetherapy #hematology. More:.
0
0
0
@CGT_Live
CGTLive®
12 days
ICYMI:. The study is open to patients aged 18 years and older who have clinically diagnosed #SolidTumors of various types and require antitumor therapy on a routine basis. #oncology #celltherapy #solidtumor #ClinicalTrialsInProgress. Read more:.
Tweet media one
0
0
0
@CGT_Live
CGTLive®
12 days
ICYMI:. Both deaths occurred in patients who were nonambulatory at the time of treatment and who had been hospitalized within 2 months of treatment in relation to raised levels of transaminases. #Duchenne #MuscularDystrophy #genetherapy @Sarepta . More:.
0
0
0